Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ragwitek (SCH 39641) in Ragweed-Induced Rhinoconjunctivitis
NCT00783198Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Sep 2009
- Primary completion
- May 2011
- Modality
- Allergy Immunotherapy
01
Overview
Phase 3, randomised, double-blind trial of ambrosia artemisiifolia allergen extract in allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by ALK-Abelló. Primary endpoint: Total Combined Score (Symptom + Medication). Started Sep 2009; status: completed.
02
Drugs
ambrosia artemisiifolia allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00783198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783198.